KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple
“Our focus at 2seventy is giving as much time as possible to patients who are battling cancer. We are moving rapidly to expand our clinical study program to determine utility of Abecma in newly diagnosed multiple myeloma patients with suboptimal response to transplant,” said Steve Bernstein, chief medical officer, 2seventy bio. “This population currently makes up more than half of multiple myeloma patients receiving transplant. Given the efficacy data from our collective KarMMa studies and well-established and predictable safety profile seen in studies replicated in the real-world, we believe there is tremendous potential for Abecma to help some of these patients earlier in their treatment path.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.